Day one will focus on setting the context for a discussion of C-peptide as an endpoint in clinical trials for new-onset T1D, first highlighting the unmet need for disease modifying therapies in new-onset T1D and C-peptide’s characteristics as a biomarker. Then we will look at how trials in this space are currently conducted, what we have learned from previous studies, the impact of technologies such as insulin pumps and continuous glucose monitors, and other practical considerations related to trial conduct.